Expanding one’s Horizons: The Tipline for 16 May 2023

Gone are the days of rebuking divestitures to manufacturers of KitKats and TidyCats. The Biden Administration set out in search of new theories of harm for challenging pharmaceutical mergers beyond requiring divestitures for overlapping medicines. Now, it appears the Federal Trade Commission believes it found a strong match. Bloomberg reports the commission will sue to block Amgen’s $27.8 billion purchase of Horizon Therapeutics later today, focused on broader harms to the development of new treatments. Divestiture buyers need not apply.

Unlock unlimited access to all Global Competition Review content